Predict your next investment

HEALTHCARE | Drug Discovery
guavatechnologies.com

See what CB Insights has to offer

Founded Year

1998

Stage

Acquired - II | Acquired

Total Raised

$65M

About Guava Technologies

Guava Technologies aims to provide Personal Cell Analysis (PCA) products that have broad applications in life science cell biology research & development . Unlike the matured market for gene-based products, the cell analysis market is still in the early stage of growth. Similar to the Apple Personal Computer which expanded the market by making computing accessible to professional end users outside of the mainframe environment, Guava's affordable designed cell analysis system aims to provide hands-on access to cell biologists outside of the centralized core cell analysis labs.

Guava Technologies Headquarter Location

25801 Industrial Boulevard

Hayward, California, 94545,

United States

510-576-1400

Latest Guava Technologies News

Millipore Takes Over Guava Technologies for $22.6M

Aug 30, 2013

(Page 1 of 1) Millipore  will pay $22.6 million to acquire Guava Technologies, a provider of benchtop cell-analysis systems. The acquisition follows the distribution and co-development partnership the two companies entered in March 2008 to bring flow cytometry to cellular biologists. “Our vision is to make flow cytometry less expensive, easier to use, and more accessible for all research scientists,” says Jonathan DiVincenzo, president of Millipore’s bioscience division. “Additionally, by developing kits that are optimized for key research areas such as stem cell research, cancer biology, cell health, and biomarker discovery, scientists will no longer need to source reagents and develop their own assays. We exceeded our targets for placing Guava instruments in 2008 and we are excited about further increasing the adoption of our flow cytometry platform by accelerating our investments in R&D, sales, and marketing.” Guava’s technology may be used to develop new products for the process monitoring tools segment of Millipore’s bioprocess division. The company expects to maintain Guava’s manufacturing and commercial operations in Hayward, CA. Guava generated approximately $22 million in sales during 2008. The transaction is expected to be slightly accretive to Millipore’s non-GAAP earnings per share this year and is expected to close in the next two weeks. ---

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Guava Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Guava Technologies is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Guava Technologies Patents

Guava Technologies has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/10/2007

7/21/2009

Flow cytometry, Cell biology, Hematology, Blood tests, Medical tests

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/10/2007

00/00/0000

Grant Date

7/21/2009

00/00/0000

Title

Subscribe to see more

Related Topics

Flow cytometry, Cell biology, Hematology, Blood tests, Medical tests

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.